Home Cart Sign in  
Chemical Structure| 471-05-6 Chemical Structure| 471-05-6

Structure of Zerumbone
CAS No.: 471-05-6

Chemical Structure| 471-05-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Zerumbone, a monocyclic sesquiterpene compound isolated from the rhizomes of Zingiber zerumbet Smith, potently inhibits the activation of Epstein-Barr virus with an IC50 of 0.14 mM. Zerumbone has anti-cancer, antioxidant, anti-inflammatory and anti-proliferative activity[1][2].

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Zerumbone

CAS No. :471-05-6
Formula : C15H22O
M.W : 218.33
SMILES Code : CC(/C=C/1)(C)C/C=C(C)/CC/C=C(C)/C1=O
MDL No. :MFCD03700769

Safety of Zerumbone

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H372-H410
Precautionary Statements:P273-P301+P312+P330-P305+P351+P338-P314
Class:9
UN#:3077
Packing Group:

Related Pathways of Zerumbone

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Huh7 50 µM 24 and 48 hours Induced cell cycle arrest and apoptosis Mol Cancer Res. 2018 Feb;16(2):256-268
MHCC-LM3 50 µM 24 hours Inhibited PI3K/AKT/mTOR and STAT3 signaling pathways Mol Cancer Res. 2018 Feb;16(2):256-268
Murine bone marrow-derived macrophages 10-50 µM 1 hour pretreatment followed by LPS or LPS/ATP treatment Suppressed the production of IL-6, TNF-α, and IL-1β Front Pharmacol. 2021 May 11;12:652860
J774A.1 cells 20 and 40 µM 1 hour pretreatment followed by LPS treatment for 2 hours Inhibited the phosphorylation of ERK, did not affect the phosphorylation of JNK and p38 MAPK Front Pharmacol. 2021 May 11;12:652860
Murine peritoneal macrophages 10-50 µM 1 hour pretreatment followed by LPS treatment for 24 hours Inhibited the production of NO and IL-6, varied effects on TNF-α depending on concentration Front Pharmacol. 2021 May 11;12:652860
J774A.1 cells 10-50 µM 1 hour pretreatment followed by LPS treatment for 24 hours Suppressed the production of IL-6, increased TNF-α production at high doses Front Pharmacol. 2021 May 11;12:652860
J774A.1 cells 10-50 µM 1 hour pretreatment followed by LPS treatment for 24 hours Inhibited the production of NO, IL-6, and PGE2, suppressed the expression of iNOS and COX-2 Front Pharmacol. 2021 May 11;12:652860
J774A.1 cells 0-50 µM 1 hour pretreatment followed by LPS/ATP or LPS/nigericin treatment Suppressed the secretion of IL-1β, inhibited the activation of NLRP3 inflammasome Front Pharmacol. 2021 May 11;12:652860
Human neuroblastoma SH-SY5Y cells 1 µM 24 hours To investigate the effect of MSC on apoptosis in Clu-knockdown SH-SY5Y cells. Results showed that 1 μM MSC could reverse the decrease in antioxidative capacity, Bcl-2/Bax ratio, and increase in caspase-8 activity caused by Clu-knockdown, thereby inhibiting apoptosis and maintaining cell viability. Invest New Drugs. 2022 Apr;40(2):224-231
Mouse neuroblastoma N2a cells 1 µM 24 hours To investigate the effect of MSC on apoptosis in Clu-knockdown N2a cells. Results showed that 1 μM MSC could reverse the decrease in antioxidative capacity, Bcl-2/Bax ratio, and increase in caspase-8 activity caused by Clu-knockdown, thereby inhibiting apoptosis and maintaining cell viability. Invest New Drugs. 2022 Apr;40(2):224-231
Primary microglial cells 1, 3, or 10 μg/ml 24 hours Zerumbone significantly reduced the production of IL-1β and TNF-α while increasing IL-10 production, and dose-dependently increased the mRNA levels of CD206, IL-10, and ARG-1, demonstrating its anti-inflammatory effects and ability to promote an anti-inflammatory phenotype in primary microglial cells. J Neuroinflammation. 2020 Feb 17;17(1):61
N9 microglial cell line 1, 3, or 10 μg/ml 24 hours Zerumbone significantly suppressed NO production and dose-dependently decreased the mRNA levels of IL-1β, IL-6, iNOS, and TNF-α, while increasing the mRNA levels of CD206, IL-10, and ARG-1, indicating its anti-inflammatory effects and ability to promote a switch in microglial phenotype from pro-inflammatory to anti-inflammatory. J Neuroinflammation. 2020 Feb 17;17(1):61
U87MG cells 10-50 µM 24 hours Zerumbone decreased the viability of U87MG cells in a dose-dependent manner. J Biomed Sci. 2012 Oct 5;19(1):86
GBM8401 cells 10-50 µM 24 hours Zerumbone induced apoptosis in GBM8401 cells in a dose-dependent manner, confirmed by MTT assay and flow cytometry. J Biomed Sci. 2012 Oct 5;19(1):86
SH-SY5Y neuroblastoma cells 8 mg/ml 24 hours To investigate the effect of Zerumbone on the expression of α2A-adrenergic, TRPV1, and NMDA NR2B receptors in LPS-induced SH-SY5Y neuroblastoma cells. Results showed that Zerumbone significantly increased the expression of α2A-adrenergic receptors while down-regulating TRPV1 and NMDA NR2B receptors. Front Pharmacol. 2020 Mar 4;11:92
HCT116 colon cancer cells 5, 10, 20 µM 24 hours To investigate the inhibitory effect of Zerumbone on the proliferation of HCT116 cells and its association with TNF-α. Results showed that with increasing concentration of Zerumbone, there was a reduction in HCT116 cell proliferation and higher TNF-α inhibition. Sci Rep. 2018 Mar 6;8(1):4090
L929 cells 30.5 ± 1.5 µM (IC50) 24 hours To assess the toxicity of Zerumbone on normal L929 cells, results showed lower toxicity in normal cells. Cell Prolif. 2019 Mar;52(2):e12558
HeLa cells 14.2 ± 0.5 µM (IC50) 24 hours To evaluate the inhibitory effect of Zerumbone on HeLa cell proliferation, results showed selective inhibition through enhanced cellular uptake. Cell Prolif. 2019 Mar;52(2):e12558
FaDu cells 10, 30, 100 µM 24 hours (apoptosis assay), 48 hours (qPCR, Western blot, ELISA analyses), 14 days (plate clone formation assay) Tilianin inhibited FaDu cell proliferation and induced apoptosis in a dose-dependent manner. It upregulated pro-apoptotic factors Bax and Bad, downregulated anti-apoptotic factors Bcl-2 and Bcl-xL, activated caspase-3 and PARP, and stimulated cytochrome c release, thereby inducing apoptosis via the mitochondrion-dependent intrinsic apoptotic pathway. Nutrients. 2022 Dec 19;14(24):5402
Helicobacter pylori 60190 6.25, 12.5, 25, 50, 100 µM 3 days Determine the minimal inhibitory concentration (MIC) of Zerumbone, which was 50 µM in agar dilution and 100 µM in broth dilution Molecules. 2021 May 1;26(9):2663
HT29/C1 cells 6.25 µM 3 hours Suppressed BFT-induced NF-κB signaling and IL-8 secretion but did not affect E-cadherin cleavage. Int J Mol Sci. 2019 Sep 14;20(18):4560
Candida albicans (CaR) 128 µg/mL 5, 10, 20 min To assess the effect of Zerumbone on fluconazole-resistant Candida albicans biofilms. Results showed that ZER at 128 µg/mL reduced cellular viability by approximately 36.99% and decreased insoluble biomass (13%), proteins (18%), water-soluble polysaccharides (65%), alkali-soluble polysaccharides (10%), and extracellular DNA (23%) in CaR biofilms. J Fungi (Basel). 2023 May 16;9(5):576
Candida albicans (CaS) 256 µg/mL 5, 10, 20 min To assess the effect of Zerumbone on fluconazole-susceptible Candida albicans biofilms. Results showed that ZER at 256 µg/mL reduced cellular viability by approximately 38.51% and decreased total biomass (57%), insoluble biomass (45%), water-soluble polysaccharides (65%), proteins (18%), and extracellular DNA (78%) in CaS biofilms. J Fungi (Basel). 2023 May 16;9(5):576
RAW 264.7 cells 2.5~20 µM 6 hours Zerumbone inhibited iNOS and COX-2 protein expressions and reduced NO and PGE2 production, while inducing HO-1 expression. Int J Mol Sci. 2016 Feb 18;17(2):249
HepG2 14 µM 72 hours Inhibited HCC cell proliferation by G2/M phase arrest and inducing apoptosis Mol Cancer Res. 2018 Feb;16(2):256-268

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
ICR mice Chronic constriction injury (CCI)-induced neuropathic pain model Intraperitoneal injection 10 mg/kg Single administration, behavioral tests conducted 30 minutes after administration To investigate the anti-allodynic and antihyperalgesic effects of Zerumbone in the CCI-induced neuropathic pain model and its mechanisms. Results showed that Zerumbone exerted anti-neuropathic effects by modulating α1-, α2-, β1-, and β2-adrenoceptors as well as TRPV1 and NMDA NR2B receptors. Front Pharmacol. 2020 Mar 4;11:92
ICR mice Chronic constriction injury (CCI)-induced neuropathic pain model Intraperitoneal injection 10 mg/kg Single administration, behavioral tests conducted 30 minutes post-administration To elucidate the mechanisms underlying zerumbone’s antineuropathic actions via cannabinoid and PPAR receptors. Results showed that zerumbone exerts anti-allodynic and antihyperalgesic effects against mechanical allodynia and thermal hyperalgesia through CB1, PPARα, and PPARγ receptors. Molecules. 2021 Jun 24;26(13):3849
Male ICR mice Chronic constriction injury (CCI)-induced neuropathic pain model Intraperitoneal injection 10 mg/kg Single administration, tests performed 30 minutes post-administration To investigate the analgesic effects of Zerumbone via potassium channels and opioid receptors in CCI-induced neuropathic pain. Results showed that Zerumbone significantly alleviated mechanical allodynia and thermal hyperalgesia. Molecules. 2020 Aug 26;25(17):3880
ICR mice Acetic acid-induced writhing response model Intraperitoneal injection 10 or 50 mg/kg Single dose Zerumbone significantly reduced the number of acetic acid-induced writhing responses. Int J Mol Sci. 2016 Feb 18;17(2):249
Male albino mice ZEA-induced hepatotoxicity model Oral gavage 15 mg/kg Once daily for 4 weeks ZER exhibited a protective effect against ZEA-induced toxicity by ameliorating inflammation and oxidative stress-induced apoptosis. ZER decreased the levels of alkaline phosphatase and alanine aminotransferase (ALT) in serum and attenuated the inflammatory response by significantly reducing the levels of pro-inflammatory factors, including IL-1β, IL-6, and TNF-α. Additionally, ZER reduced the hepatic malondialdehyde (MDA) concentration and increased the activities of superoxide dismutase (SOD), glutathione (GSH), and catalase (CAT). ZER also alleviated ZEA-induced apoptosis by regulating the PI3K/AKT pathway and the expression of Nrf2 and HO-1. Antioxidants (Basel). 2021 Oct 12;10(10):1593
NSG mice Subcutaneous and orthotopic HCC xenograft models Intraperitoneal injection 20 mg/kg/day Once daily for 3 weeks Suppressed HCC xenograft growth and lung metastasis Mol Cancer Res. 2018 Feb;16(2):256-268
APP/PS1 transgenic mice Alzheimer's disease model Oral gavage 25 mg/kg Once daily for 20 days Zerumbone significantly ameliorated deficits in both non-cognitive and cognitive behaviors in transgenic APP/PS1 mice, reduced β-amyloid deposition, attenuated pro-inflammatory microglial activation in the cortex and hippocampus, and increased the proportion of anti-inflammatory microglia. Additionally, zerumbone downregulated the expression of key MAPK pathway molecules such as p38 and ERK. J Neuroinflammation. 2020 Feb 17;17(1):61
Wistar albino rats Collagen-induced arthritis (CIA) model Oral 25 mg/kg and 50 mg/kg Once daily for 20 days To evaluate the therapeutic effects of Zerumbone on collagen-induced arthritis. Results showed that Zerumbone significantly reduced the clinical severity of arthritis, decreased oxidative stress and inflammatory cytokine levels, and restored normal histology in joints and tissues. ACS Omega. 2023 Jan 10;8(3):2982-2991
C57BL/6 mice ETBF infection-induced colitis model Oral 30 or 60 mg/kg Once daily for 7 days Zerumbone reduced ETBF-induced colonic inflammation, prevented weight loss and splenomegaly, reduced colonic inflammation with decreased macrophage infiltration, and decreased expression of IL-17A, TNF-α, KC, and iNOS, while inhibiting NF-κB signaling. Int J Mol Sci. 2019 Sep 14;20(18):4560

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.58mL

0.92mL

0.46mL

22.90mL

4.58mL

2.29mL

45.80mL

9.16mL

4.58mL

 

Historical Records

Categories